About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 56 record(s)
Req # A-2021-000047
An aggregated list of all non-cannabis ingredients that have or are used in inhalable cannabis extracts, as well as the frequency of their use.Organization: Health Canada
October 2021
Req # A-2021-000318
Data from medical device incident reporting for all medical devices from February 3, 2020 until June 2, 2021 with the following information or fields: Sex (including null or unknown responses), Incident ID, Device, Device Type, Company Name, Hazard…Organization: Health Canada
October 2021
Req # A-2021-000494
The current Health Canada approved Risk Management Plan on file for Soliris (eculizumab).Organization: Health Canada
October 2021
Req # A-2021-000906
Documents that address Health Canada protocols for interception or seizure of 5-MeO-DMT, including, but not limited to, agency protocols for: training related to the seizure of 5-MeO-DMT, search, notification, testing, storage, destruction, return…Organization: Health Canada
October 2021
Req # A-2021-000953
A list of company identifiers, each with a count of their Class-II medical device licences, qualified as follows: counting only those Class II medical device licences for which the scope statement of the respective QMS (Quality Management System)…Organization: Health Canada
October 2021
Req # A-2019-001517
Adverse Drug Reaction (ADR). Report number: E2B_02405078.Organization: Health Canada
October 2021
Req # A-2019-001696
Adverse Reaction Reports (AERs). Report numbers: E2B_02764833, E2B_02764834, E2B_02764835.Organization: Health Canada
October 2021
Req # A-2020-001407
Adverse Drug Reactions (ADRs) for Fosamax. Report numbers: E2B_01498392, E2B_01497348, E2B_01550413, E2B_01559129, E2B_01560554, E2B_01560565, E2B_01563727, E2B_01563841, E2B_01565657, E2B_01566184, E2B_01567431, E2B_01568489, E2B_01575803,…Organization: Health Canada
October 2021
Req # A-2021-000282
Adverse Drug Reaction (ADR) for PLAQUENIL. Report number: E2B_03706156.Organization: Health Canada
October 2021
Req # A-2021-000353
Adverse Drug Reaction (ADR) for ROSUVASTATIN CALCIUM. Report number: E2B_03467451.Organization: Health Canada
October 2021